Ingredient or product comparison
Best Research Peptides for Skin Brightening: Mechanism Comparison
Reduced L-glutathione (GSH) Tyrosinase competitive inhibition 22–27% at 12 weeks 4–6 weeks Low. No rebound observed in RCTs 2017 RCT (60 subjects, oral + topical), Journal of Clinical and Aesthetic Dermatology 2019 meta-analysis Kojic acid tripeptide-1 Tyrosin
This source-based comparison does not add ratings or recommend a winner.
- Reduced L-glutathione (GSH)
- Tyrosinase competitive inhibition
- 22–27% at 12 weeks
- 4–6 weeks
- Low. No rebound observed in RCTs
- 2017 RCT (60 subjects, oral + topical), Journal of Clinical and Aesthetic Dermatology 2019 meta-analysis
- Kojic acid tripeptide-1
- Tyrosinase copper chelation
- 31% at 8 weeks (UV-induced)
- 6–8 weeks
- Low
- 2020 Japanese Dermatology Society trial
- Nonapeptide-1 (Melanostatyn-5)
- MC1R inverse agonism, melanosome transfer disruption
- 15–19% at 8 weeks
- 8–10 weeks
- Very low. Effect persists post-treatment
- 2016 in vitro (Pigment Cell & Melanoma Research), 2018 Korean clinical trial
- Hexapeptide-2
- MITF transcription factor suppression
- 19–24% at 12 weeks
- 8–12 weeks
- Low. Sustained effect after discontinuation
- 2018 Korean PIH trial (45 subjects)
- Alpha-MSH antagonists (cyclic heptapeptide, investigational)
- MC1R competitive antagonism
- 41% reduction in UV-induced melanin (explant model)
- Preventive use. Applied pre-UV
- Unknown. Insufficient clinical data
- 2021 Journal of Investigative Dermatology
- Professional Assessment
- Tyrosinase inhibitors (GSH, kojic tripeptide) show the fastest measurable results and strongest evidence base. Melanosome disruptors work more slowly but maintain effect longer after stopping. Alpha-MSH antagonists represent next-generation prevention but lack finished formulations for current research use.